Laborie Medical Technologies Inc.

Laborie Acquires the JADA® System for Rapid Postpartum Hemorrhage Control, Expanding Obstetrics Portfolio

Laborie Medical Technologies Corp (“Laborie”) today announced the closing of the previously announced acquisition of the JADA® System, marking a major milestone in expanding the company’s obstetrics portfolio. The post Laborie Acquires the JADA® System for Rapid Postpartum Hemorrhage Control,…

Laborie Announces Agreement to Acquire the JADA® System from Organon

Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (“Laborie”) announced it has entered into an agreement with Organon, a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, to acquire the…

Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon

Landmark procedures launch the ENDURE 1 clinical study evaluating Optilume’s safety and feasibility as a new minimally invasive option for patients with benign ureteric strictures. The post Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon appeared…

Laborie Appoints Chris Smith as Chief Executive Officer

Laborie Medical Technologies Corp., a global leader in medical technology, today announced the appointment of Chris Smith as Chief Executive Officer, effective September 22, 2025. Smith succeeds Michael Frazzette, who announced his retirement last month. The post Laborie Appoints Chris Smith as…

Laborie’s Optilume® Drug-Coated Balloon for Stricture Secures Coverage from BCBS of Michigan

Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie Medical Technologies’ Optilume® Urethral Drug-Coated Balloon for Stricture to eligible Commercial HMO members. This new coverage reinforces…

Three-Year Data from ROBUST III Confirms Long-Term Durability of Optilume® Drug-Coated Balloon for Recurrent Urethral Strictures

Laborie Medical Technologies Corp. (Laborie), a global leader in diagnostic and therapeutic urology, announced the publication of three-year outcomes from the ROBUST III randomized controlled trial in the Journal of Endourology. The results underscore the long-term durability and safety of the…